Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingGlobeNewsWire • 04/24/24
FREELINE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLNPRNewsWire • 01/26/24
FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLNBusiness Wire • 11/28/23
FRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to ShareholdersBusiness Wire • 11/22/23
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressGlobeNewsWire • 10/25/23
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressGlobeNewsWire • 10/16/23
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseGlobeNewsWire • 10/04/23
Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/15/23
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher DiseaseGlobeNewsWire • 07/25/23
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson's DiseaseGlobeNewsWire • 06/26/23
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 06/13/23
Freeline Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 05/30/23
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher DiseaseGlobeNewsWire • 05/22/23